Cas:7790-31-0 Aagnesium iodide hexahydrate manufacturer & supplier

We serve Chemical Name:Aagnesium iodide hexahydrate CAS:7790-31-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Aagnesium iodide hexahydrate

Chemical Name:Aagnesium iodide hexahydrate
CAS.NO:7790-31-0
Synonyms:Aagnesium iodide hexahydrate
Molecular Formula:MgI26H2O
Molecular Weight:386.21
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Aagnesium iodide hexahydrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Aagnesium iodide hexahydrate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Aagnesium iodide hexahydrate Use and application,Aagnesium iodide hexahydrate technical grade,usp/ep/jp grade.


Related News: China has a complete upstream and downstream industry chain, lower costs, and good talent reserves. It is one of the few industries in China that has an advantage in international competition. Aagnesium iodide hexahydrate manufacturer China has a complete upstream and downstream industry chain, lower costs, and good talent reserves. It is one of the few industries in China that has an advantage in international competition. Aagnesium iodide hexahydrate supplier International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation. Aagnesium iodide hexahydrate vendor Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs. Aagnesium iodide hexahydrate factory The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.